February 2005
Worldwide Biotech;Feb2005, Vol. 17 Issue 2, p1
Trade Publication
Presents information on the license agreement signed by GPC Biotech AG with Debiopharm SA for the pre-clinical small molecule major histocompatibility complex class II antagonists program for the treatment of autoimmune diseases. Scope and terms of the agreement; Details of the therapeutic mechanism of the small molecule MHC class II antagonists program; Background of the companies.


Related Articles

  • Debiopharm Technology to Turn Injectable Drugs into Oral Formulations.  // Drug Discovery & Development;Nov2002, Vol. 5 Issue 10, p21 

    Reports that Debiopharm SA has announced the licensing of a technology based on the formulation of microparticles prepared with blends of biodegradable and polycationic polymers. Applications and uses of the technology.

  • GPC Draws $10M Up Front In Japanese Marketing Deal. Osborne, Randall // BioWorld Today;6/26/2007, Vol. 18 Issue 123, p1 

    The article reports on a licensing deal signed by GPC Biotech Inc. with Japan's Yakult Honsha Co. Ltd. for its prostate cancer drug satraplatin. Report says that Yakult will pay GPC as reimbursement for past expenses related to satraplatin. The Japanese company will also pay all development,...

  • $270M GPC-Celgene Deal Fizzles. Gaudio, Thomas // njbiz;8/11/2008, Vol. 21 Issue 33, p2 

    This article announces that Celgene Corp. has ended its co-development and licensing agreement with GPC Biotech for the cancer drug satraplatin. The agreement is valued at $269.8 million. Particular focus is given to the decision of Celgene to withdrew the drug's marketing application in Europe....

  • GPC Biotech receives termination notice from Celgene.  // PharmaWatch: Biotechnology;Sep2008, Vol. 7 Issue 9, p17 

    The article reports on the intention of Celgene Corp. to terminate its co-development and license agreement with GPC Biotech AG for satraplatin in Europe, Turkey and Middle East. Celgene has sent a notification to GPC regarding the move. GPC will retain all the licensing rights in these territories.

  • GPC Biotech invests $2 million on launch of phase III trial of Satraplatin.  // PharmaWatch: Cancer;November 2003, Vol. 2 Issue 11, p22 

    Reports that Spectrum Pharmaceuticals Inc. has received payment from GPC Biotech AG after the treatment of the first patient in the satraplatin phase III hormone-refractory prostate cancer trial. Amount received by Spectrum; Spectrum's plans to expand its generic drug portfolio; Terms of the...

  • OTHER NEWS TO NOTE.  // BioWorld Today;11/6/2009, Vol. 20 Issue 215, p2 

    This section offers news briefs on the biotechnology industry as of November 6, 2009. The U.S. Food and Drug Administration (FDA) granted orphan drug designation to the chemotherapy agent Abraxane from Abraxis BioScience Inc. Agennix AG and GPC Biotech AG completed their merger. Compugen Ltd....

  • GPC BIOTECH GETS GERMANY PERMITS FOR MONOCLONAL ANTIBODY.  // Worldwide Biotech;Oct2003, Vol. 15 Issue 10, p5 

    Reports that GPC Biotech AG has received three permits from the responsible German regulatory agency for the company's fully human oncology monoclonal antibody, 1D09C3, as of October 2003.

  • GPC Biotech: satraplatin approval delay could prove costly.  // PharmaWatch: Monthly Review;Sep2007, Vol. 6 Issue 9, p7 

    The article reports that the New Drug Application for prostate cancer drug satraplatin was withdrawn by the GPC Biotech after an advisory panel's recommendation to wait for overall survival data before it can be approved. The GPC Biotech is making an effort to obtain the data quickly because it...

  • Agreements/contracts.  // Medical Device Daily;6/20/2012, Vol. 16 Issue 117, p3 

    The article reports that Immune Express Group of Australia, Debiopharm Group of Switzerland and Biocartis of Belgium have reported a global exclusive, royalty-bearing license for the late-stage development and commercialization of a multiplex gene expression assay called SeptiCyte Triage.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics